Lorlatinib in ALK-Rearranged Lung Cancer

descriptionPublicationkeyboard_double_arrow_right Article 01 Jan 2021 English Publisher:Elsevier BVJournal:Cancer Cell, volume 39, pages 25-27 (issn: 1535-6108,

Copyright policy )

Authors: Shelley, Kuang; Natasha B, Leighl;

doi: 10.1016/j.ccell.2020.12.017

pmid: 33434512

Lorlatinib in ALK-Rearranged Lung Cancer

- Summary
- Subjects
- Metrics

Abstract

Should lorlatinib be the standard first-line treatment in advanced ALK-rearranged lung cancer? In the New England Journal of Medicine, Shaw et al. present interim analysis results from CROWN, a randomized, phase 3 study comparing lorlatinib with crizotinib as initial therapy in patients with advanced ALK-rearranged NSCLC.

Related Organizations

Keywords

Lung Neoplasms, Crizotinib, Lactams, Lactams, Macrocyclic, Aminopyridines, Humans, Pyrazoles, Anaplastic Lymphoma Kinase

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	12
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Top 10%
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Top 10%